A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Drug Screening Using IMD in Bladder Cancer
- Status
- ENROLLING_BY_INVITATION
- Phase
- EARLY_PHASE1
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study of ASP1012 in Adults With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2